TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01063283

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Pemetrexed 500 mg/m\^2 intravenously over 10 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Pemetrexed 500 mg/m\^2 intravenously over 10 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin at a dose calculated to produce an area under the concentration-time curve of 6 mg/ml•min intravenously over 30 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin at a dose calculated to produce an area under the concentration-time curve of 6 mg/ml•min intravenously over 30 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab 7.5 mg/kg
Description: Bevacizumab at 7.5 mg/kg intravenously over 90 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab 7.5 mg/kg
Description: Bevacizumab at 7.5 mg/kg intravenously over 90 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab 15 mg/kg
Description: Bevacizumab at 15 mg/kg intravenously over 90 minutes
Study: NCT03783624

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypnosis
Description: A 6 session course of individual hypnosis therapy will be offered.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Open label placebo
Description: Ritual intake of 2 placebo capsules twice a day
Study: NCT05343624

Intervention type: DEVICE
Group type: OTHER
Intervention: continuous glucose monitoring
Description: Use of continuous glucose monitoring in inpatient and ICU settings
Study: NCT00862082

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PR104 550 mg/m^2 + sorafenib
Description: 550 mg/m\^2 PR104 IV on day 1 of each 28 day cycle + 400 mg sorafenib PO twice daily. Number of Cycles: until progression or unacceptable toxicity develops.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PR104 770 mg/m^2 + sorafenib
Description: 770 mg/m\^2 PR104 IV on day 1 of each 28 day cycle + 400 mg sorafenib PO twice daily. Number of Cycles: until progression or unacceptable toxicity develops.
Study: NCT04551209

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Maintaining apical patency
Description: In apical patency group, a size 10 K file will be passed beyond the apical foramen between each instrument change to maintain apical patency while in Non apical patency group, K file will be carried up to the working length only. A final peri-apical radiograph will be taken in the group A with the 10 K patency file 01mm beyond the apical foramen to confirm patency.
Study: NCT00787267

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: 70 mg PO twice daily until progression. Re-assess radiographically every 6 weeks.
Study: NCT02703441

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tablet computer
Description: Patients randomized to the intervention group will receive a tablet computer with an app-like software solution supporting nutrition and physical activity. The patients operate the computer and order their meals from the hospital menu; register dietary intake, and receive feedback informing about their current status for protein and energy intake. Likewise, the patients use small series of brief videos instructing in daily life activities for strengthening their muscles. After this, they register their performed activities and will receive informing and motivating feedback. Nudging and prompting is part of the solution.
Study: NCT03098004

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: e-Cigarette
Description: Participants will self-administer an experimenter-provided e-cigarette.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: e-Cigarette
Description: Participants will self-administer an experimenter-provided e-cigarette.
Study: NCT03202615

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L (lactoferrin)
Description: Dietary Supplement: Pravotin sachets (Hygint, Egypt) containing bLf One sachet of Pravotin contains 100 mg of bLf. Dosage: one sachet twice a day before meals with placebo tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: F (ferrous sulphate)
Description: Drug: FerroGrad by Abbott Dosage: one capsule three times /day containing150 mg of dried ferrous sulfate capsules (Ferrofol capsules, Eipico, Egypt), with placebo sachets.
Study: NCT00334113

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TLC-PED
Description: Telephone-Linked Care - Promoting Exercise for Diabetes (TLC-PED), a method that uses interactive voice response and speech recognition technologies, will be developed to provide individualized and personalized motivational messages using automated telephone calls for veterans with Type 2 diabetes who participate in a home based walking program.
Study: NCT02776397

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin E
Description: Two hundred patients will be recruited to a pilot randomized controlled trial (RCT), stratified by Hp 2-2 phenotype status (100 Hp 2-2 and 100 non-Hp 2-2), and randomly allocated in a 1:1 ratio to either vitamin E 400 IU supplementation daily for 6 months or a placebo group. The trial will determine whether vitamin E improves the aforementioned surrogate markers in the Hp phenotype strata.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin E
Description: Two hundred patients will be recruited to a pilot randomized controlled trial (RCT), stratified by Hp 2-2 phenotype status (100 Hp 2-2 and 100 non-Hp 2-2), and randomly allocated in a 1:1 ratio to either vitamin E 400 IU supplementation daily for 6 months or a placebo group. The trial will determine whether vitamin E improves the aforementioned surrogate markers in the Hp phenotype strata.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo arm

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo arm
Study: NCT00865280

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTK 0796
Description: PTK 0796 100 mg for injection; PTK 0796 tablet 150 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: linezolid
Description: For gram positive treatment: Linezolid 600 mg tablets and pre-mixed 600 mg IV infusion solution; For gram negative treatment: Moxifloxacin 400 mg tablets and pre-mixed 400mg IV infusion solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: moxifloxacin
Description: moxifloxacin 400 mg tablet; moxifloxacin 400 mg IV infusion solution
Study: NCT02792829

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: All participants will receive one single dose in each of the 2 treatment periods (total of 2 doses). The total duration of the treatment periods is 12 days (6 days per period) in healthy adult volunteers.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: All participants will receive one single dose in each of the 2 treatment periods (total of 2 doses). The total duration of the treatment periods is 12 days (6 days per period) in healthy adult volunteers.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: All participants will receive one single dose in each of the 2 treatment periods (total of 2 doses). The total duration of the treatment periods is 12 days (6 days per period) in healthy adult volunteers.
Study: NCT02358941

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neurofeedback training
Description: In neurofeedback training, EEG-activity is visualized and fed back to the participant online on a computer screen. Successful regulation is rewarded by bonus points. The aim is to gain control over one's brain activity and to be able to switch to or to maintain a more wakeful, alert or focussed state.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neurofeedback training
Description: In neurofeedback training, EEG-activity is visualized and fed back to the participant online on a computer screen. Successful regulation is rewarded by bonus points. The aim is to gain control over one's brain activity and to be able to switch to or to maintain a more wakeful, alert or focussed state.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerized cognitive training
Description: In computerized cognitive training, impaired neuropsychological functions, such as inhibition, working memory, distractibility, are directly trained by adaptive computerized software programs. We use training programs from a scientifically based training system for patients presenting problems with sustained, focussed or selective attention, working memory, inhibition, processing speed. Good performance / improvements are rewarded with bonus points.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerized cognitive training
Description: In computerized cognitive training, impaired neuropsychological functions, such as inhibition, working memory, distractibility, are directly trained by adaptive computerized software programs. We use training programs from a scientifically based training system for patients presenting problems with sustained, focussed or selective attention, working memory, inhibition, processing speed. Good performance / improvements are rewarded with bonus points.
Study: NCT04083768

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 15° and 30° wedge sponges
Description: After the spinal anesthesia is completed, the wedge sponge is placed between the patient's pelvis and ribs and the wedge is removed before the skin is cut.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 15° and 30° wedge sponges
Description: After the spinal anesthesia is completed, the wedge sponge is placed between the patient's pelvis and ribs and the wedge is removed before the skin is cut.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: 15° and 30° wedge sponges
Description: After the spinal anesthesia is completed, the wedge sponge is placed between the patient's pelvis and ribs and the wedge is removed before the skin is cut.
Study: NCT02644876

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Penehyclidine inhalation
Description: Penehyclidine inhalation will be administered by inhalation (penehyclidine hydrochloride 0.5 mg/0.5 ml, mixed with normal saline 5.5 ml) once every 12 hours from the night before surgery till the second day after surgery. The total number of inhalation is seven times. Study drug inhalation is performed with the high-flow oxygen-driven method for the non-intubated patients or with the atomizing inhalation device of ventilator for the intubated patients.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo inhalation
Description: Placebo inhalation will be administered by inhalation (water for injection 0.5 ml, mixed with normal saline 5.5 ml) once every 12 hours from the night before surgery till the second day after surgery. The total number of inhalation is seven times. Study drug inhalation is performed with the high-flow oxygen-driven method for the non-intubated patients or with the atomizing inhalation device of ventilator for the intubated patients.
Study: NCT00653926

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ropivacaine, ketorelac and epinephrine
Description: In Group A, 200 mg ropivicaine, 30 mg ketorelac and 0.5 mg epinephrine (total volume 106 ml) are infiltrated by the surgeon into the soft tissues peri-articularly during the operation in the following way: Before inserting the components, 20-30 ml are injected into the posterior capsule and before closure of the wound the rest is injected into the capsule incision, the synovium, the ligament and the subcutaneous tissue After 21 postoperative hours in Group A, 150 mg ropivicaine, 30 mg ketorelac and 0.1 mg epinephrine, total volume 22 ml, are injected intraarticularly via the catheter.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: In Group P (placebo) no injections were given intaoperatively. All patients had a tunnelled intra-articular multihole 20-G catheter placed at the end of the operation by the surgeon.After 21 postoperative hours 22 ml of saline was injected intraarticularly via the catheter.
Study: NCT02210494

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secretrol
Study: NCT03759353

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Baseline ferritin level
Description: At enrollment, baseline serum ferritin level will be assessed to quantify iron deficiency.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Baseline ferritin level
Description: At enrollment, baseline serum ferritin level will be assessed to quantify iron deficiency.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactoferrin
Description: lactoferrin 100 mg one sachet twice daily for 30 days to be dissolved in 1/4 glass of water before meals (Pravotin, Hygint pharmaceuticals).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous Sulfate
Description: 200 mg of dried ferrous sulphate tablet once daily for 30 days on empty stomach but may be taken with meals to avoid stomach upset.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Follow up ferritin level
Description: Four weeks after treatment, serum ferritin level will be assessed to quantify effect if treatment on iron status.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Follow up ferritin level
Description: Four weeks after treatment, serum ferritin level will be assessed to quantify effect if treatment on iron status.
Study: NCT01518764

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Red Wine Polyphenols 600mg/day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT03181529

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: Participants will receive a moderately high psilocybin dose in the first session and will receive either a moderately high or high psilocybin dose in the second session.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: Participants will receive a moderately high psilocybin dose in the first session and will receive either a moderately high or high psilocybin dose in the second session.
Study: NCT03126318

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: COR-001
Description: Anti-inflammatory therapy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile water with a final buffer of 25 mM Histidine, 8.5% (w/v) trehalose and 0.05% PS80
Study: NCT01420211

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Primovist® 0,25 mmol/ml solution for injection
Description: intravenous bolus injection of 25 µmol/kg (=0,1 ml/kg) body weight Primovist® and blood sampling before (serum blank) and 6, 11, 21, 31, 45, 65, 95, 125 min and 3, 4, 6, 8, 12, 24 and 48 h after drug administration

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: lmaging of 20 slices (thickness: 3 mm; max. time of imaging 10 s) before and 0.25, 1, 2, 3, 4, 5, 7, 8, 9, 10, 20, 30, 40, 50, 60, 90 and 120 min after intravenous bolus injection of 25 µmol/kg (=0,1 ml/kg) body weight Primovist®
Study: NCT02843516

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT01678495

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sulfur hexafluoride + ultrasounds

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant tissue plasminogen activator

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant tissue plasminogen activator
Study: NCT04298476

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placement of an adductor canal nerve block
Description: An adductor canal nerve block will be placed in a patient undergoing a knee arthroscopy in 1 of 3 locations with local anesthetic or placebo (without location definition or local anesthetic) to assess optimal placement of local anesthetic, pain management and anxiety scores post operatively.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Placement of an adductor canal nerve block
Description: An adductor canal nerve block will be placed in a patient undergoing a knee arthroscopy in 1 of 3 locations with local anesthetic or placebo (without location definition or local anesthetic) to assess optimal placement of local anesthetic, pain management and anxiety scores post operatively.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Placement of an adductor canal nerve block
Description: An adductor canal nerve block will be placed in a patient undergoing a knee arthroscopy in 1 of 3 locations with local anesthetic or placebo (without location definition or local anesthetic) to assess optimal placement of local anesthetic, pain management and anxiety scores post operatively.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Placement of an adductor canal nerve block
Description: An adductor canal nerve block will be placed in a patient undergoing a knee arthroscopy in 1 of 3 locations with local anesthetic or placebo (without location definition or local anesthetic) to assess optimal placement of local anesthetic, pain management and anxiety scores post operatively.
Study: NCT04180124

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walking
Description: Patients walk over ground on a mat with sensors and on a treadmill with sensors (in different conditions) to compare their movement pattern.~Also the movement pattern will be compared between walking at comfortable walking speed en fast walking.~Finally, the correlation between upper extremity impairment and arm swing will be investigated.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walking
Description: Patients walk over ground on a mat with sensors and on a treadmill with sensors (in different conditions) to compare their movement pattern.~Also the movement pattern will be compared between walking at comfortable walking speed en fast walking.~Finally, the correlation between upper extremity impairment and arm swing will be investigated.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walking
Description: Patients walk over ground on a mat with sensors and on a treadmill with sensors (in different conditions) to compare their movement pattern.~Also the movement pattern will be compared between walking at comfortable walking speed en fast walking.~Finally, the correlation between upper extremity impairment and arm swing will be investigated.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walking
Description: Patients walk over ground on a mat with sensors and on a treadmill with sensors (in different conditions) to compare their movement pattern.~Also the movement pattern will be compared between walking at comfortable walking speed en fast walking.~Finally, the correlation between upper extremity impairment and arm swing will be investigated.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walking
Description: Patients walk over ground on a mat with sensors and on a treadmill with sensors (in different conditions) to compare their movement pattern.~Also the movement pattern will be compared between walking at comfortable walking speed en fast walking.~Finally, the correlation between upper extremity impairment and arm swing will be investigated.
Study: NCT01026324

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dinaciclib
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT05938205

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: AA-1
Description: low dose aminoacids

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: AA-2
Description: high dose aminoacids

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Nutritional Placebo

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exe-H
Description: high intensity physical exercise

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exe-H
Description: high intensity physical exercise

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exe-H
Description: high intensity physical exercise
Study: NCT03204864

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RLD Group
Description: patients CS placement will be guided by RLD measurement. Physician will place the CS lead in the site of longest RLD with a stable and acceptable pacing threshold.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional CS lead placement
Description: Clinical Practice
Study: NCT01585857

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous adipose derived stem cells administrated for intra-articular use
Description: Each patient will receive one single administration of the cells and will be followed for 3 months. Each patients will be follow-up during one year with routinely examinations for safety issues.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous adipose derived stem cells administrated for intra-articular use
Description: Each patient will receive one single administration of the cells and will be followed for 3 months. Each patients will be follow-up during one year with routinely examinations for safety issues.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous adipose derived stem cells administrated for intra-articular use
Description: Each patient will receive one single administration of the cells and will be followed for 3 months. Each patients will be follow-up during one year with routinely examinations for safety issues. The first patient will be followed during 12 weeks before inclusion of the second patient.
Study: NCT02093819

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to BI 416970
Description: single rising doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 416970
Description: single rising doses
Study: NCT00794313

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amantadine 300 mg
Description: Amantadine, 300 mg, capsule, three times a day, two weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amantadine 300 mg
Description: Amantadine, 300 mg, capsule, three times a day, two weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate
Description: Topiramate, 25 mg, capsule, two times a day, 1 week Sugar Pill, capsule, one time a day, 1 week Topiramate, 50 mg, capsule, three times a day, 1 week

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar Pill
Description: sugar pill, capsule, three times a day, 2 weeks
Study: NCT02964169

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Planning Support